Michal Gilon Ohev Zion
Chief Tech/Sci/R&D Officer at BioCancell Therapeutics, Inc.
Profile
Michal Gilon Ohev Zion is currently the Vice President-Research & Development at BioCancell Therapeutics, Inc. She previously worked as the Vice President-Research & Development at Anchiano Therapeutics Ltd.
Dr. Gilon Ohev Zion received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Michal Gilon Ohev Zion active positions
| Companies | Position | Start |
|---|---|---|
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Chief Tech/Sci/R&D Officer | 2013-01-31 |
Former positions of Michal Gilon Ohev Zion
| Companies | Position | End |
|---|---|---|
| ANCHIANO THERAPEUTICS LTD. | Chief Tech/Sci/R&D Officer | - |
Training of Michal Gilon Ohev Zion
| The Hebrew University of Jerusalem | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Health Technology |
- Stock Market
- Insiders
- Michal Gilon Ohev Zion
